• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to join the Department of Radiology at Cambridge University (UK) for a lecture on June 22, 2022

by last | Mar 15, 2022 | 2022, Past Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “From encoded combinatorial libraries to clinical-stage radiopharmaceuticals”

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

by mfantozzi | Jan 7, 2022 | 2022, Press Releases, Scientific

More info here

Philogen to participate at the Italian Top Picks Event organised by Stifel on January 17, 2022

by last | Jan 5, 2022 | 2022, Past Events

Co-founder, CEO and CSO, Prof. Dario Neri and CFO Laura are giving a 1 hour presentation on January 17, 2022 at 16:00 CET.

Philogen to participate at the Italian Mid Cap Conference organised by Mediobanca on January 19-20, 2022

by last | Jan 5, 2022 | 2022, Past Events

The Italian Midcap Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri  and CFO Laura Baldi through a series of one-on-one meetings. Mediobanca Italian Mid Cap Conference 

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

by last | Nov 24, 2021 | 2022, Press Releases

20211124_PR_Philochem_Janssen_DEL

Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

by last | Aug 23, 2021 | 2022, Press Releases

Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer.
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch